工程益生菌大肠杆菌 (Escherichia coli) 用于使用 RiboJ 增强的遗传电路来产生对炎症敏感的酸
Seung-Gyun Woo1,2, Seong Keun Kim1, Seung-Goo Lee3,4,5
1Synthetic Biology Research Center and the K-Biofoundry, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, 34141, Republic of Korea.
Journal of biological engineering
|January 21, 2025
概括
工程化益生菌现在产生酸 (IAA) 作为对肠道炎症信号的反应. 这一发展为治疗炎症性肠道疾病提供了一个有希望的新策略.
科学领域:
- 微生物学 微生物学
- 合成生物学 合成生物学
- 胃肠病学 胃肠病学
背景情况:
- 我们越来越了解肠道微生物群在健康中的代谢作用.
- 越来越多的兴趣在工程益生菌的治疗应用.
- 专注于通过微生物代谢物调节肠道环境.
研究的目的:
- 工程师埃舍里希亚大肠杆菌尼斯尔1917 (EcN) 制造酸 (IAA).
- 诱导IAA的产生,以应对特定的肠道炎症生物标志物:硫酸盐和酸盐.
- 开发一个响应良好的益生菌系统,用于潜在的炎症性肠病治疗.
主要方法:
- 构建了由炎症信号触发的IAA合成的遗传电路.
- 在EcN中优化了异质IAA生物合成途径.
- 加入了一个RiboJ绝缘体,以提高IAA的产量.
- 开发了一个可诱导IAA的基因电路,使用Pseudomonas putida 1290的IACR转录因子进行监测.
主要成果:
- 工程 EcN 菌株在暴露于硫酸盐和酸盐时成功产生 IAA 水平的增加.
- 证明了一种能够感知并对肠道炎症作出反应的益生菌的概念证明.
- 建立了一个实时监控IAA生产的系统.
结论:
- 工程 EcN 证明了作为胃肠道炎症的活生物治疗产品的潜力.
- 进一步精细化可能会导致基于IAA的实地疗法.
- 这种方法为针对性治疗炎症性肠道疾病提供了一个有希望的策略.
相关概念视频
Stringent Response in E. coli
Bacterial growth is closely tied to nutrient availability, with cells proliferating exponentially under favorable conditions and entering a stationary phase when resources become scarce. This transition is mediated by a regulatory mechanism known as the stringent response, which allows bacteria to adapt to nutrient deprivation by modulating gene expression and metabolic activity.During nutrient scarcity, intracellular amino acid levels decline. It results in the accumulation of uncharged tRNAs...
Bioreactor Controls-III
Strain improvement is a foundational strategy in industrial microbiology aimed at maximizing microbial productivity, particularly because natural isolates typically yield commercially valuable products in very low concentrations. Although optimizing the culture medium and environmental conditions can improve yields, these adjustments are inherently limited by the organism’s genetic potential. As a result, the focus shifts toward genetic modifications to enhance biosynthetic capacity. The...
Production of Antibiotics
Penicillin, one of the earliest and most widely used antibiotics, is produced industrially by the filamentous fungus Penicillium chrysogenum. Large stirred-tank bioreactors ranging from tens to hundreds of thousands of liters maintain tightly controlled temperature, pH, and dissolved oxygen conditions to support fungal metabolism and maximize antibiotic yield. Penicillin is a secondary metabolite, synthesized primarily during the stationary growth phase, which requires a carefully managed...
Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
iChip
The cultivation of environmental microorganisms has long been hindered by the inability to replicate complex native conditions in vitro. The isolation chip (iChip) addresses this limitation by facilitating the growth of previously uncultivable microorganisms through in situ incubation. Designed for high-throughput microbial cultivation, the iChip comprises hundreds of microchambers, each capable of housing a single microbial cell. These microchambers are loaded with a mixture of molten agar and...
Bacterial Gastroenteritis
Bacterial gastroenteritis, characterized by diarrhea, abdominal cramps, and vomiting, is often caused by ingestion of contaminated food or water and is frequently associated with pathogenic Escherichia coli strains. These microbes exploit two principal mechanisms to inflict disease.Shiga toxin–producing E. coli, also referred to as STEC—notably O157:H7—release Shiga toxins that target ribosomes, blocking protein synthesis. The B subunit of the toxin binds the host glycolipid receptor...


